Drug Trial Radar · NCT00006145
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
Last checked: Nov 20, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Aug 2000
Primary completion
Not stated
Study completion Feb 2006
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in people with HIV.
Conditions
- Cytomegalovirus Infections
- HIV Infections
Interventions
ValganciclovirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
57 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Therapeutics CRS
Birmingham, Alabama
USC CRS
Los Angeles, California
UCLA CARE Center CRS
Los Angeles, California
Stanford CRS
Palo Alto, California
Ucsd, Avrc Crs
San Diego, California
Ucsf Aids Crs
San Francisco, California
Santa Clara Valley Med. Ctr.
San Jose, California
San Mateo County AIDS Program
San Mateo, California
Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic
San Rafael, California
University of Colorado Hospital CRS
Aurora, Colorado
Georgetown University CRS (GU CRS)
Washington D.C., District of Columbia
Univ. of Miami AIDS CRS
Miami, Florida
The Ponce de Leon Ctr. CRS
Atlanta, Georgia
Univ. of Hawaii at Manoa, Leahi Hosp.
Honolulu, Hawaii
Northwestern University CRS
Chicago, Illinois
Cook County Hosp. CORE Ctr.
Chicago, Illinois
Rush Univ. Med. Ctr. ACTG CRS
Chicago, Illinois
Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana
Indiana Univ. School of Medicine, Wishard Memorial
Indianapolis, Indiana
Methodist Hosp. of Indiana
Indianapolis, Indiana
Univ. of Iowa Healthcare, Div. of Infectious Diseases
Iowa City, Iowa
IHV Baltimore Treatment CRS
Baltimore, Maryland
Johns Hopkins Adult AIDS CRS
Baltimore, Maryland
Massachusetts General Hospital ACTG CRS
Boston, Massachusetts
Bmc Actg Crs
Boston, Massachusetts
BMC, Div. of Ped Infectious Diseases
Boston, Massachusetts
Beth Israel Deaconess Med. Ctr., ACTG CRS
Boston, Massachusetts
Brigham and Women's Hosp. ACTG CRS
Boston, Massachusetts
SSTAR, Family Healthcare Ctr.
Fall River, Massachusetts
University of Minnesota, ACTU
Minneapolis, Minnesota
Washington U CRS
St Louis, Missouri
Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.
Omaha, Nebraska
SUNY - Buffalo, Erie County Medical Ctr.
Buffalo, New York
Beth Israel Med. Ctr., ACTU
New York, New York
Cornell CRS
New York, New York
NY Univ. HIV/AIDS CRS
New York, New York
Weill Med. College of Cornell Univ., The Cornell CTU
New York, New York
Columbia Univ., HIV Prevention and Treatment Medical Ctr.
New York, New York
AIDS Care CRS
Rochester, New York
McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit
Rochester, New York
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.